Clinical Trials Browser

Phase 1/2 × Negative T790M Mutation and Met Amplification × Clear all

NCT04338243 2020-04-08

Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors

Phase 1/2 Unknown

Negative T790M Mutation and Met Amplification